U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H48O3
Molecular Weight 456.7003
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of .BETA.-BOSWELLIC ACID

SMILES

[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@]5(C)CC[C@@]34C)[C@@]1(C)CC[C@@H](O)[C@]2(C)C(O)=O

InChI

InChIKey=NBGQZFQREPIKMG-PONOSELZSA-N
InChI=1S/C30H48O3/c1-18-10-13-26(3)16-17-28(5)20(24(26)19(18)2)8-9-21-27(4)14-12-23(31)30(7,25(32)33)22(27)11-15-29(21,28)6/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21-,22-,23-,24+,26-,27-,28-,29-,30-/m1/s1

HIDE SMILES / InChI

Molecular Formula C30H48O3
Molecular Weight 456.7003
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 11 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Β-boswellic acid (β-BA) is one of the active triterpenoid compounds from the extract of boswellia serrate, known in Indian Ayurvedic system of medicine as Salai guggal. Beta-boswellic acid has been indicated in apoptosis of cancer cells. β-boswellic acid belonds to class of boswellic acids exhibiting anti-inflammatory activities, which are in the phase II clinical trial for study of safety and tolerability in subjects with Relapsing Remitting Multiple Sclerosis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
23.9 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Mechanism of antiinflammatory actions of curcumine and boswellic acids.
1993 Mar
Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study.
1998 Nov 17
Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells.
2002 Dec
Effects of Boswellia serrata in mouse models of chemically induced colitis.
2005 Apr
Patents

Patents

Sample Use Guides

8 months of treatment at three times a day dose of between 400-1600 mg
Route of Administration: Oral
β-boswellic acid (β-BA) significantly increases nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). HEUVCs were pretreated with β-BA (25 and 50 uM) for 24 h before being subjected to 6 h OGD then incubated with β-BA for an additional 24 h. NO production was measured by DAF-FM DA. The amount of NO was evaluated by measuring the fluorescence intensity excited at 495 nm and emitted at 515 nm.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:07:44 GMT 2023
Edited
by admin
on Sat Dec 16 05:07:44 GMT 2023
Record UNII
B252M1YO2V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
.BETA.-BOSWELLIC ACID
MI  
Common Name English
.BETA.-BOSWELLIC ACID (CONSTITUENT OF BOSWELLIA SERRATA) [DSC]
Common Name English
URS-12-EN-24-OIC ACID, 3.ALPHA.-HYDROXY-
Common Name English
3.ALPHA.-HYDROXYURS-12-EN-24-OIC ACID
Common Name English
BETA-BOSWELLIC ACID
Common Name English
URS-12-EN-23-OIC ACID, 3-HYDROXY-, (3.ALPHA.,4.BETA.)-
Common Name English
.BETA.-BOSWELLIC ACID [MI]
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID2057578
Created by admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
PRIMARY
MERCK INDEX
m2628
Created by admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
PRIMARY Merck Index
PUBCHEM
168928
Created by admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
PRIMARY
CAS
631-69-6
Created by admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
PRIMARY
FDA UNII
B252M1YO2V
Created by admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
PRIMARY